Jeremy Cohen, Rinaldo Bellomo, Laurent Billot, Louise M Burrell, David M Evans, Simon Finfer, Naomi E Hammond, Qiang Li, David Liu, Colin McArthur, Brett McWhinney, John Moore, John Myburgh, Sandra Peake, Carel Pretorius, Dorrilyn Rajbhandari, Andrew Rhodes, Manoj Saxena, Jacobus P J Ungerer, Morag J Young, Balasubramanian Venkatesh
Rationale: Whether biomarkers can identify subgroups of patients with septic shock with differential treatment responses to hydrocortisone is unknown. Objectives: To determine if there is heterogeneity in effect for hydrocortisone on mortality, shock resolution, and other clinical outcomes based on baseline cortisol, aldosterone, and ascorbic acid concentrations. Methods: From May 2014 to April 2017, we obtained serum samples from 529 patients with septic shock from 22 ICUs in Australia and New Zealand. Measurements and Main Results: There were no significant interactions between the association with 90-day mortality and treatment with either hydrocortisone or placebo for total cortisol (odds ratio [OR], 1...
September 1, 2020: American Journal of Respiratory and Critical Care Medicine